col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


30 Results       Page 1

 [1] 
The Royal Society of Chemistry: RSC Medicinal Chemistry
  original article Date Title Authors   All Authors
1 [GO] 2025―Feb―13 Transmembrane protease serine 2 (TMPRSS2) inhibitors screened from an Fv-antibody library for preventing SARS-CoV-2 infection Jaeyong Jung, Jeong Soo Sung, Soonil Kwon, Hyung Eun Bae, Min-Jung Kang, Joachim Jose, et al. (+2)
2 [GO] 2024―Dec―23 Targeting host integrated stress response: lead discovery of flavonoid compounds active against coronaviruses PEDV and PDCoV Liang Yi, Yishuai Wang, Jiehuang Wang, Yihan Chen, Weixue Huang, Ying Liao, Qingwen Zhang
3 [GO] 2024―Oct―18 Miniaturized Click Chemistry and Direct Screening Facilitate the Discovery of Triazole Piperazine SARS-CoV-2 Mpro Inhibitors with Improved Metabolic Stability Shenghua Gao, Letian Song, Bing Ye, Mianling Yang, Junyi Li, Manyu Gu, et al. (+4)
4 [GO] 2024―Sep―27 Discovery of a Nasal Spray Steroid, Tixocortol, as an Inhibitor of SARS-CoV-2 Main Protease and Viral Replication David A Davis, Ashwin Nair, Yana Astter, Emma Treco, Brian Daniel Peyser, Rick Gussio, et al. (+9)
5 [GO] 2024―Sep―26 Exploring 7β-Amino-6-Nitrocholestens as COVID-19 Antivirals: In silico, Synthesis, Evaluation, and Integration of Artificial Intelligence (AI) in Drug Design: Assessing the Cytotoxicity and Antioxidant Activity of 3β-Acetoxynitrocholestane Shahabuddin ., Uzma ., Mohammad Azam, mehtab parveen, N.H.A. Kadir, Kim Min, Mahboob Alam
6 [GO] 2024―Sep―16 Inhibition of SARS-CoV-2 3CLpro by chemically modified tyrosinase from Agaricus bisporus David Aguilera-Rodriguez, David Ortega-Alarcon, Angela Vazquez-Calvo, Veronica Ricci, Olga Abian, Adrian Velazquez-Campoy, et al. (+2)
7 [GO] 2024―Sep―03 Asymmetric imidazole-4,5-dicarboxamides derivatives as SARS-CoV-2 main protease inhibitors: Design, Synthesis and Biological Evaluation Phuong Nguyen Hoai Huynh, Phatcharin Khamplong, Minh-Hoang Phan, Thanh-Phuc Nguyen, Phuong Vu Ngoc Lan, Quang-Vinh Tang, et al. (+7)
8 [GO] 2024―Aug―26 Preventing SARS-CoV-2 infection using Fv-antibodies targeting the proprotein convertase (PPC) cleavage site Jaeyong Jung, Jeong Soo Sung, Soonil Kwon, Hyung Eun Bae, Min-Jung Kang, Joachim Jose, et al. (+2)
9 [GO] 2024―Aug―16 Inhibiting SARS-CoV-2 viral entry by targeting spike:ACE2 interaction with O-modified quercetin derivatives Reuben James Z. Rosal, Monissa C. Paderes
10 [GO] 2024―Aug―01 Discovery of highly potent SARS-CoV-2 nsp14 methyltransferase inhibitors based on adenosine 5′-carboxamides Hugo Kocek, Dominika Chalupská, Milan Dejmek, Alexandra Dvořáková, Michala Zgarbová, Michal Šála, et al. (+12)
11 [GO] 2024―Apr―29 Identification of SARS-CoV-2 Mpro inhibitors through deep reinforcement learning for de novo drug design and computational chemistry approaches Julien Hazemann, Thierry Kimmerlin, Roland Lange, Aengus MacSweeney, Geoffroy Bourquin, Daniel Ritz, Paul Czodrowski
12 [GO] 2024―Jan―26 N-arylsulfonamide-based adenosine analogues to target RNA cap N7-methyltransferase nsp14 of SARS-CoV-2 Rostom Ahmed-Belkacem, Joris Troussier, Adrien Delpal, Bruno Canard, Jean-Jacques Vasseur, Etienne DECROLY, Françoise Debart
13 [GO] 2023―Nov―28 NMR 1H,19F-based screening of the four stem-looped structure 5_SL1-SL4 located in the 5′-untranslated region of SARS-CoV 2 RNA Daniel Hymon, Jason Martins, Christian Richter, Sridhar Sreeramulu, Anna Wacker, Jan Ferner, et al. (+3)
14 [GO] 2023―Oct―13 On the origins of SARS-CoV-2 main protease inhibitors Yves L. Janin
15 [GO] 2023―Aug―17 Identification of Novel 1,2,3-triazole Isatin Derivatives as Potent SARS-CoV-2 3CLpro Inhibitors via Click-chemistry-based Rapid Screening Xiangyi Jiang, Jing Li, Antonio Viayna, F. Javier Luque, Molly Woodson, Lanlan Jing, et al. (+8)
16 [GO] 2023―Jul―31 De novo design of a stapled peptide targeting SARS-CoV-2 spike protein receptor-binding domain Ravindra Thakkar, Dilip K. Agarwal, Chathuranga B. Ranaweera, Susumu Ishiguro, Martin Conda-Sheridan, Natasha N. Gaudreault, et al. (+3)
17 [GO] 2023―May―16 Silver N-heterocyclic carbene complexes are potent uncompetitive inhibitors of the papain-like protease with antiviral activity against SARS-CoV-2 Maria Gil-Moles, Cillian O'Beirne, Igor V. Esarev, Petra Lippmann, Matthias Tacke, Jindrich Cinatl Jr., et al. (+2)
18 [GO] 2023―Mar―21 Insights Into Targeting the SARS-CoV-2: Design, Synthesis, In Silico Studies and Antiviral Evaluation of New Dimethylxanthine Derivatives Abdalla R. Mohamed, Ahmed Mostafa, Mahmoud A. El Hassab, Gomaa M. Hedeab, Sara H. Mahmoud, Riham F. George, et al. (+3)
19 [GO] 2023―Jan―25 Design and Synthesis of Naturally-Inspired SARS-CoV-2 Inhibitors Haitham Hassan, Jeanne Chiaravalli, Afnan Hassan, Loay Bedda, Tim Krischuns, Kuang-Yu Chen, et al. (+9)
20 [GO] 2022―Nov―18 Synthesis of bis-furyl-pyrrolo[3,4-b]pyridin-5-ones via Ugi-Zhu Reaction and In Vitro Activity Assays Against Human SARS-CoV-2 and In Silico Studies on its main Proteins Ivette Morales-Salazar, Flora P. Montes-Enríquez, Carlos E. Garduño-Albino, M. A. Garcia-Sanchez, Ilich A. Ibarra, Yareli Rojas-Aguirre, et al. (+6)
21 [GO] 2022―Oct―27 Advances in research on 3C-like protease (3CLpro) inhibitors against SARS-CoV-2 since 2020 Roufen Chen, Yali Gao, Han Liu, He Li, Wenfa Chen, Junjie Ma
22 [GO] 2022―Oct―14 Design, Synthesis and Immunological Evaluation of Monophosphoryl Lipid A Derivatives as Adjuvants for RBD-hFc Based SARS-CoV-2 Vaccine Shiwei Su, Liqing Chen, Menglan Yang, Dan Liang, Bixia ke, Zhongqiu Liu, et al. (+4)
23 [GO] 2022―Jan―25 An insight into SARS-CoV2 structure, Pathogenesis, target hunting for drug development and vaccine initiatives Arijit Ghosh, Paritosh k. Kar, Anupam Gautam, Rahul Gupta, Rajveer Singh, Rudra chakravarti, et al. (+4)
24 [GO] 2021―Sep―07 Synthesis of low-molecular weight fucoidan derivatives and their binding abilities to SARS-CoV-2 spike proteins Tatsuki Koike, Aoi Sugimoto, Shuhei Kosono, Sumika Komaba, Yuko Kanno, Takashi Kitamura, et al. (+4)
25 [GO] 2021―Aug―20 Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors Bing Bai, Elena Arutyunova, Muhammad Bashir Khan, Jimmy Lu, Michael A. Joyce, Holly Saffran, et al. (+11)
26 [GO] 2021―Aug―18 A novel compound active against SARS-CoV-2 targeting Uridylate-specific endoribonuclease (NendoU/NSP15): In silico and in vitro investigations Sumit Kumar, Yash Gupta, Samantha Zak, Charu Upadhyay, Neha Sharma, Andrew Herbert, et al. (+6)
27 [GO] 2021―Apr―15 A review of latest research on Mpro targeted SARS-COV inhibitors Huihui Yang, Jinfei Yang
28 [GO] 2020―Dec―21 Repurposing the HCV NS3-4A protease drug boceprevir as COVID-19 therapeutics Rick Oerlemans, Angel Jonathan Ruiz-Moreno, Yingying Cong, Nilima Dinesh Kumar, Marco A. Velasco-Velazquez, Constantinos G. Neochoritis, et al. (+4)
29 [GO] 2020―Dec―17 Targeting the SARS-CoV-2-spike protein: from antibodies to miniproteins and peptides Sebastian Pomplun
30 [GO] 2020―Nov―02 Identification of LASSBio-1945 as an inhibitor of SARS-CoV-2 main protease (MPRO) through in silico screening supported by molecular docking and a fragment-based pharmacophore model Lucas S. Franco, Rodolfo C. Maia, Eliezer J. Barreiro
 [1] 

30 Results       Page 1


[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.003 sec